Manifold Bio

Manifold Bio

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.manifold.bio

Last Round

Series A

Jul 14, 2022

Total Funding Raised

$45.4M

Momentum Score

25 /100

Company Overview

Manifold Bio is a biotechnology company that offers a platform for enhanced measurement across all phases of drug development, enabling the multiplexed tracking and quantification of numerous protein designs to accelerate patient recovery through advanced protein engineering techniques.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, ML Platforms, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Infrastructure

Keywords

in vivo screeningprotein barcodingAI protein designbiologics design platformmCodeshigh-throughput screeningAI drug discoverytargeted biologicsgenerative biologyprotein therapeuticsbrain shuttlesdrug discovery platformin vivo discoverytargeted drug deliverymultiplexed screeningdrug discovery partnershipsbiodistributiononcology therapeuticsneurodegenerative diseases

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Manifold Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Manifold Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AJul 14, 2022
SeedSep 8, 2020

Key People

Founding team and executive leadership

Pierce Ogden

Co-Founder, CTO And Board Director

Founding Team

Gleb Kuznetsov

Co-Founder And CEO

Founding Team

Manifold Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Generative antibody design model mBER is now available.

  • Nov 3, 2025

    Focuses on AI-guided drug discovery through a license agreement.

Manifold Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Manifold Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Manifold Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range62
Year Founded2019
Last FundingJul 14, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.